References
- Gurwitz D , McLeodHL. Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics10 , 157–159 (2009).
- He YJ , McLeodHL. Ready when you are: easing into preemptive pharmacogenetics. Clin. Pharmacol. Ther.92 , 412–414 (2012).
- Ge D , FellayJ, ThompsonAJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 , 399–401 (2009).
- Daly AK , DonaldsonPT, BhatnagarP et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet.41 , 816–819 (2009).
- Baldwin RM , OwzarK, ZembutsuH et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18 , 5099–5109 (2012).
- Brown CC , HavenerTM, MedinaMW et al. A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet. Genomics 22 , 796–802 (2012).
- Green ED , Guyer MS; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature470 , 204–213 (2011).
- Emond MJ , LouieT, EmersonJ et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat. Genet. 44(8) , 886–889 (2012).
- Morag A , Pasmanik-ChorM, Oron-KarniV, RehaviM, StinglJC, GurwitzD. Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics12 , 171–184 (2011).
- Clark SL , AdkinsDE, AbergK et al. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol. Med. 42 , 1151–1162 (2012).
- Perez-Gracia JL , Gloria Ruiz-Ilundain M, Garcia-Ribas I, Maria Carrasco E. The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research. Cancer95 , 1605–1610 (2002).
- Li D , LewingerJP, GaudermanWJ et al. Using extreme phenotype sampling to identify the rare causal variants of quantitative traits in association studies. Genet. Epidemiol. 35 , 790–799 (2011).
- Barnett IJ , LeeS, LinX. Detecting rare variant effects using extreme phenotype sampling in sequencing association studies. Genet. Epidemiol.37 , 142–151 (2013).
- Gurwitz D , PirmohamedM. Pharmacogenomics: the importance of accurate phenotypes. Pharmacogenomics11 , 469–470 (2010).
- Roden DM , XuH, DennyJC, WilkeRA. Electronic medical records as a tool in clinical pharmacology: opportunities and challenges. Clin. Pharmacol. Ther.91 , 1083–1086 (2012).
- Suhre K , ShinSY, PetersenAK et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477 , 54–60 (2011).
- Tukiainen T , KettunenJ, KangasAJ et al. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum. Mol. Genet. 21 , 1444–1455 (2012).
- Kettunen J , TukiainenT, SarinAP et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44 , 269–276 (2012).
- Chen R , MiasGI, Li-Pook-ThanJ et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148 , 1293–1307 (2012).
- Ball MP , ThakuriaJV, ZaranekAW et al. A public resource facilitating clinical use of genomes. Proc. Natl Acad. Sci. USA 109 , 11920–11927 (2012).